Anti-inflammatory strategies in coronary atherosclerosis

Current Opinion in Investigational Drugs

Volumn 3, Issue 12, 2002, Pages 1725-1728

  Burton, Paul B J ^a   Daniel, Thomas O ^a  

^a AMGEN INC   (United States)

Author keywords

Acute coronary syndrome; Atherosclerosis; C reactive protein; Cytokines; NSTEMI; STEMI

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; AMOXICILLIN; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; AZITHROMYCIN; C REACTIVE PROTEIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEAT SHOCK PROTEIN; HEPARIN; MATRIX METALLOPROTEINASE; METRONIDAZOLE; TIROFIBAN; TOLL LIKE RECEPTOR; TROPONIN;

ACUTE DISEASE; ANTIBIOTIC THERAPY; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ATHEROSCLEROTIC PLAQUE; CELLULAR IMMUNITY; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BYPASS SURGERY; CORONARY ARTERY DISEASE; DISEASE COURSE; DRUG CONTRAINDICATION; DRUG EFFECT; EVIDENCE BASED MEDICINE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HIGH RISK PATIENT; HUMAN; HUMORAL IMMUNITY; INFLAMMATION; INFLAMMATORY INFILTRATE; INHIBITION KINETICS; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; REVIEW; RISK ASSESSMENT; SEX DIFFERENCE; SIGNAL TRANSDUCTION; ST SEGMENT ELEVATION; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT PLANNING; UNSTABLE ANGINA PECTORIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CORONARY ARTERIOSCLEROSIS; HUMANS; INFLAMMATION; SIGNAL TRANSDUCTION;

EID: 0036999973     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Lloyd-Jones DM, Larson MG, Beiser A, Levy D: Lifetime risk of developing coronary heart disease. Lancet (1999) 353(9147):89-92.
2. Théroux P, Willerson JT, Amrstrong PW: Progress in the treatment of acute coronary syndromes: A 50-year perspective (1950-2000). Circulation (2000) 102(20 Suppl 4):IV2-IV13.
3. Ottani F, Galvani M, Nicolini FA, Ferrini D, Pozzati A, Di Pasquale G, Jaffe AS: Elevated cardiac troponin levels predict the risk of adverse outcome in patients with acute coronary syndromes. Am Heart J (2000) 140(6):917-927.
4. Burke AP, Farb A, Malcom GT, Liang YH, Smialek J, Virmani R: Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med (1997) 336(18):1276-1282.
5. Kolodgie FD, Burke AP, Farb A, Gold HK, Yuan J, Narula J, Finn AV, Virmani R: The thin-cap fibroatheroma: A type of vulnerable plaque: The major precursor lesion to acute coronary syndromes. Curr Opin Cardiol (2001) 16(5):285-292.
6. Chester MR, Chen L, Tousoulis D, Poloniecki J, Kaski JC: Differential progression of complex and smooth stenoses within the same coronary tree in men with stable coronary artery disease. J Am Coll Cardiol (1995) 25(4):837-842.
7. Biasucci LM, Liuzzo G, Grillo RL, Caligiuri G, Rebuzzi AG, Buffon A, Summaria F, Ginnetti F, Fadda G, Maseri A: Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation (1999) 99(7):855-860. Profiles the onset and timecourse of the elevation of CRP levels at discharge and the association between this and subsequent myocardial events.
8. Vorchheimer DA, Fuster V: Inflammatory markers in coronary artery disease. Let prevention douse the flames. J Am Med Assoc (2001) 286(17):2154-2156.
9. Agrawal A, Shrive AK, Greenhough TJ, Volanakis JE: Topology and structure of the C1q-binding site on C-reactive protein. J Immunol (2001) 166(6):3998-4004.
10. Albert CM, Ma J, Rifai N, Stampfer MJ, Ridker PM: Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. Circulation (2002) 105(22):2595-2599. Compares and contrasts different potential markers of sudden cardiac death and identifies CRP as a useful marker.
11. Keaney JF, Vita JA: The value of inflammation for predicting unstable angina. N Engl J Med (2002) 347(1):55-57.
12. Inokubo Y, Hanada H, Ishizaka H, Fukushi T, Kamada T, Okumura K: Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J (2001)141(2):211-217.
13. Kai H, Ikeda H, Yasukawa H, Kai M, Seki Y, Kuwahara F, Ueno T, Sugi K, Imaizumi T: Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol (1998) 32(2):368-372.
14. Galis ZS, Khatri JJ: Matrix metalloproteinases in vascular remodeling and atherogenesis: The good, the bad, and the ugly. Circ Res (2002) 90(3):251-262.
15. Nakajima T, Schulte S, Warrington KJ, Kopecky SL, Frye RL, Goronzy JJ, Weyand CM: T-cell-mediated lysis of endothelial cells in acute coronary syndromes. Circulation (2002) 105(5):570-575. Describes the functional changes in CD4+/CD28null T-cells in patients with unstable angina and the role this plays in tissue damage that contributes to plaque destabilization.
16. Neurath MF, Finotto S, Glimcher LH: The role of Th1/Th2 polarization in mucosal immunity. Nat Med (2002) 8(6):567-573.
17. Plutzky J: Inflammatory pathways in atherosclerosis and acute coronary syndromes. Am J Cardiol (2001) 88(8A):10K-15K.
18. Blankenberg S, Tiret L, Bickel C, Peetz D, Cambien F, Meyer J, Rupprecht HJ, AtheroGene Investigators: Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation (2002) 106(1):24-30.
19. Mallat Z, Corbaz A, Scoazec A, Besnard S, Leseche G, Chvatchko Y, Tedgui A: Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation (2001) 104(14):1598-1603.
20. Mallat Z, Corbaz A, Scoazec A, Graber P, Alouani S, Esposito B, Humbert Y, Chvatchko Y, Tedgui A: Interleukin-18/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability. Circ Res (2001) 89(7):E41-E45.
21. Bar FW, Verheugt FW, Col J, Materne P, Monassier JP, Geslin PG, Metzger J, Raynaud P, Foucault J, De Zwaan C et al: Thrombolysis in patients with unstable angina improves the angiographic but not the clinical outcome. Results of UNASEM, a multicenter, randomized, placebo-controlled, clinical trial with anistreplase. Circulation (1992) 86(1):131-137.
22. Laskey WK: Debate: When should we intervene in unstable angina - Time for an old look? Curr Control Trials Cardiovasc Med (2000) 1(1):15-18.
23. Ronner E, Boersma E, Laarman GJ, Somsen GA, Harrington RA, Deckers JW, Topol EJ, Califf RM, Simoons ML: Early angioplasty in acute coronary syndromes without persistent ST-segment elevation improves outcome but increases the need for six-month repeat revascularization: An analysis of the PURSUIT trial. Platelet glycoprotein IIB/IIIA in unstable angina: Receptor suppression using integrilin therapy. J Am Coll Cardiol (2002) 39(12):1924-1929.
24. Buffon A, Biasucci LM, Liuzzo G, D'Onofrio G, Crea F, Maseri A: Widespread coronary inflammation in unstable angina. N Engl J Med (2002) 347(1):5-12. An elegant study demonstrating monocyte activation in cells flowing through an essentially normal coronary artery when an unstable lesion is in the other coronary artery.
25. Rioufol G, Finet G, Ginon I, Andre-Fouet X, Rossi R, Vialle E, Desjoyaux E, Convert G, Huret JF, Tabib A: Multiple atherosclerotic plaque rupture in acute coronary syndrome: A three-vessel intravascular ultrasound study. Circulation (2002) 106(7):804-808. As with reference [24.], this publication demonstrates directly that ACS patients probably have multiple unstable lesions in their coronary arteries.
26. Bhatt DL, Topol EJ: Need to test the arterial inflammation hypothesis. Circulation (2002) 106(1):136-140.
27. Cannon CP, Hand MH, Bahr R, Boden WE, Christenson R, Gibler WB, Eagle K, Lambrew CT, Lee TH, MacLeod B, Ornato JP et al: Critical pathways for management of patients with acute coronary syndromes: An assessment by the National Heart Attack Alert Program. Am Heart J (2002) 143(5):777-789.
28. Schaub FJ, Han DKM, Liles WC, Adams LD, Coats SA, Ramachandran RK, Seifert RA, Schwartz SM, Bowen-Pope DF: Fas/FADD-mediated activation of a specific program of inflammatory gene expression in vascular smooth muscle cells. Nat Med (2000) 6(7):790-796. Describes the effects of signals initiated by regulated FADD overexpression in rat vascular smooth muscle cells in the carotid artery and how they may contribute to the pathogenesis of vascular disease.
29. Seshiah PV, Kereiakes DJ, Vasudevan SS, Lopes N, Su BY, Flavahan NA, Goldschmidt-Clermont PJ: Activated monocytes induce smooth muscle cell death: Role of macrophage colony-stimulating factor and cell contact. Circulation (2002) 105(2):174-180. Describes a role for monocytes/macrophages activated by M-CSF in loss of vascular smooth muscle cells and the influence this may have on plaque disruption in coronary thrombosis and ACS.
30. Prasad A, Zhu J, Halcox JPJ, Waclawiw MA, Epstein SE, Quyyumi AA: Predisposition to atherosclerosis by infections: Role of endothelial dysfunction. Circulation (2002) 106(2):184-190.
31. Wick G, Perschinka H, Millonig G: Atherosclerosis as an autoimmune disease: An update. Trends Immunol (2001) 22(12):665-669.
32. Coombes BK, Chiu B, Fong IW, Mahony JB: Chlamydia pneumoniae infection of endothelial cells induces transcriptional activation of platelet-derived growth factor-β: A potential link to intimal thickening in a rabbit model of atherosclerosis. J Infect Dis (2002) 185(12):1621-1630.
33. Muhlestein JB, Anderson JL, Carlquist JF, Salunkhe K, Home BD, Pearson RR, Bunch TJ, Allen A, Trehan S, Nielson C: Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: Primary clinical results of the ACADEMIC study. Circulation (2000) 102(15):1755-1760.
34. Stone AFM, Mendall MA, Kaski JC, Edger TM, Risley P, Poloniecki J, Camm AJ, Northfield TC: Effect of treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of inflammation and cardiac events in patients with acute coronary syndromes: South Thames Trial of Antibiotics in Myocardial Infarction and Unstable Angina (STAMINA). Circulation (2002) 106(10):1219-1223.
35. Hansson GK, Libby P, Schonbeck U, Yan ZQ: Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res (2002) 91(4):281-291.